Stay updated on Nivolumab in Recurrent Nasopharyngeal Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Recurrent Nasopharyngeal Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Recurrent Nasopharyngeal Carcinoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T22:39:19.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study record related to the use of Nivolumab as a treatment for recurrent/metastatic Nasopharyngeal Carcinoma after failing 2 lines or more of previous chemotherapy.
    Difference
    0.2%
    Check dated 2024-06-06T14:43:13.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study. It now specifies that participants must have recurrent or metastatic nasopharyngeal carcinoma (NPC) incurable by local therapies and must have failed at least two lines of previous chemotherapy, including one platinum-based chemotherapy.
    Difference
    19%
    Check dated 2024-05-22T21:20:53.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:26:49.000Z thumbnail image

Stay in the know with updates to Nivolumab in Recurrent Nasopharyngeal Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Recurrent Nasopharyngeal Carcinoma Clinical Trial page.